Company / Net Income
Tandem Diabetes Care Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$204.7M
FY2025
5-year range
-$222.6M / -$24.8M
FY2021-FY2025
Trend
-113.2%
vs FY2024
Sector context
#143 of 164
Health Care
What the data says
Tandem Diabetes Care's net income of -$205M is lower than 87% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 10 years, ranging from -$223M in FY2023 to -$25M in FY2021.
Based on SEC 10-K filings.
-$205M in FY2025.
Improved from -$223M to -$205M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 164This company -$204.7M Sector average $467.5M
▼
-143.8% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 113.2% year-over-year.
- Ranks #143 out of 164 companies in the Health Care sector.
- Peak net income was recorded in FY2021.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$204.7M | -113.2% |
| FY2024 | -$96.0M | +56.9% |
| FY2023 | -$222.6M | -547.5% |
| FY2022 | -$34.4M | -38.9% |
| FY2021 | -$24.8M | +79.8% |
| FY2020 | -$122.6M | -67.9% |
| FY2019 | -$73.0M | +12.5% |
| FY2018 | -$83.4M | -15.2% |
| FY2017 | -$72.4M | +13.2% |
| FY2016 | -$83.4M | -15.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026